A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo−Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder DISORDER
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Bitopertin (Primary) ; Serotonin uptake inhibitors
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jul 2017 Status changed from recruiting to completed.
- 02 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Aug 2012 New trial record